Illumina has signed deals to genotype the sample collections at four biobanks. Each of the projects is aiming to build a repository of linked genotypic and phenotypic data, with the sequencing results generated by Illumina being paired to electronic medical records (EMRs) possessed by the owners of the biobanks.
Stallergenes Greer has resumed production at its plant that was blighted by IT problems. The restart of manufacturing comes nearly two months after regulators found the IT system introduced at the site in August was causing operational disruptions and erroneous product deliveries.
AstraZeneca has outlined how it is using the white-hot CRISPR genome editing technology to put its repositories of sequencing data to work in its R&D programs. The initiative is one of the many ways in which AstraZeneca is applying the technology at its drug discovery and development units.
DNAnexus has connected its genomics platform to Sapio Sciences' Exemplar laboratory information management system (LIMS). The integration is expected to provide clients with a sample-to-answer tracking system, a resource the collaborators see cutting costs while improving quality control.
The division, which the company has set up to meet rising demand for postapproval research, will make use of BioClinica's technology capabilities.
CosmosID has raised $6 million to advance its microbiome software business. The Series B round is intended to enable CosmosID to build out and enhance multiple aspects of its operation, with the expansion of engineering capabilities and improvement of genotype-phenotype linkage abilities high on its agenda.
Leo Pharma has placed a $70 million bet on the biopharma companies of the future providing more than just pharmacological interventions. The bet takes the form of the Leo Innovation Lab, a site at which the drugmaker will research how apps, web platforms, wearables, virtual reality, artificial intelligence and telemedicine can improve the lives of people with psoriasis.
A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.
Takeda has enlisted Broad Institute Genomic Services to analyze samples taken from patients who participated in a Phase III trial of its recently approved multiple myeloma drug, Ninlaro.
Cedars-Sinai is planning to trial the use of Fitbit Charge HR activity trackers to gauge the suitability of cancer patients for certain treatments, MobiHealthNews reports.
Discussions about the threat of cybercrime typically invoke images of armies of hackers whose sole task is to steal data from corporations based across the globe. Yet, as GlaxoSmithKline is now finding out, when solid allegations of cyber-espionage surface a more mundane image of an insider armed with just an email account and a thumb drive emerges.
BioClinica has broadened the scope of its clinical trial software suite by acquiring Clinverse. The deal gives BioClinica access to software to support financial aspects of clinical trials, a niche that Clinverse has carved out a prominent position in since setting up shop in 2008.
Big Pharma consortium TransCelerate BioPharma has released a portal through which research sites can interact with multiple clinical trial sponsors. The portal is intended to free clinical trial sites from the duplicated workload and administrative burdens associated with using a different portal for each of the sponsors with which they work.
Chipmaker Qualcomm is reportedly talking to GlaxoSmithKline about setting up a $1 billion joint venture. The deal, reports of which were posted by two financial publications, would mark a continuation of Qualcomm's drive to tighten its ties to biopharma, which was given impetus last year when it set up a VC fund with Novartis and inked a deal with Roche.
Vice President Joe Biden has put improved data sharing at the center of a government-led initiative to cure cancer. The plan is to create conditions that usher improved drugs to market by working with tech companies to pull down data silos while boosting the resources available to public and private research teams.
Illumina has outlined its plan to release a semiconductor-based sequencing system. The product, currently dubbed Firefly, will become the first Illumina sequencing system to rely on something other than optical readouts.
BioMed X has begun offering bioinformatics services on the back of its alliance with Merck KGaA. The services are underpinned by tools developed during BioMed X's three-year collaboration with Merck KGaA, during which it advanced computational approaches to the design of highly selective kinase inhibitors.
Leaders at NIH's genomics research wing are planning to funnel $240 million into the Centers for Common Disease Genomics, a newly created group focused on identifying the genetic factors involved in widespread health issues such as heart disease, diabetes, stroke and autism.
Astellas Pharma has signed its second tech-enabled drug repurposing deal in as many months. The latest deal connects Astellas to NuMedii, a digital drug discovery shop cofounded by Atul Butte that lists Allergan among its clients.
The congressional watchdog has taken the FDA to task over the IT system it uses to track the safety of approved drugs. Officials at the Government Accountability Office told the FDA it should identify IT investments that will enable regulatory staffers to "easily and systematically" access postmarket data for oversight purposes.